Ask a question
AlzeCure will present the newly published data for their pain project against osteoartritis with their novel TrkA-NAM compound ACD137, and be talking about the unmet medical need and the potential opportunities for ACD137. Presenters will be Dr Märta Segerdahl, Dr Pontus Forsell and AlzeCure’s CEO Martin Jönsson.
More on the presentations will follow and additional information on TrkA-NAM and ACD137 can be found at AlzeCure Pharma’s web site: www.alzecurepharma.com
Martin Jönsson
VD
Märta Segerdahl
CMO
Pontus Forsell
Head of Discovery